SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aviron
AVIR 3.375+1.7%Nov 11 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brad C. Dunlap who wrote (94)8/2/1997 8:43:00 PM
From: Pseudo Biologist   of 645
 
Brad, you should be thanked - just the description, from a professional perspective, on the machinery of secondary offerings is worth the "price of admission."

On valuation, it may be interesting to get an idea of how "vaccine companies" are valued. PMC was recently made into a unit of Rhone-Poulenc; I could not find the acquisition price as a multiple of sales or earnings (I think the incorporation as wholly owned unit of Rhone happened in 1994 or so, before the real explosion in web info) . PMC's website is connaught.com in case someone here wants to check on the (potential) competition.

Finally, I found an interesting quote made in 1990-1991 "Flu is not so dramatic a disease, but clearly in terms of numbers over the years, AIDS is peanuts" Who is the ignoramus who said that? You may ask. Try influenza researcher Peter Palese of the Mt. Sinai School of Medicine in NYC, cited on page 331 of Radetsky's book "The Invisible Invaders: ..." Palese still works actively in the field as one can easily check by doing a MEDLINE search - his email is given in a couple of recent papers from his labs. I have a few other juicy quotes, which I will save for slow days. And, no Peter P is not asking me (or you) to buy AVIR -g-

Max
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext